CD4 and cancer: These findings predict that the survival advantage among females with wt TP53 LUAD results from a superior capacity to combat cancer through CD8+ T cells and Natural Killer (NK) cell mediated-killing, directed through MHCI and also by CD4+ T cells through MHCII.